No Data
Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $20
BioCryst to Report Second Quarter 2024 Financial Results on August 5
United States Hereditary Angioedema Therapeutics Market Report 2024: Trends, Dynamics, Competition, Forecast and & Opportunities, 2019-2029F - ResearchAndMarkets.com
BioCryst Pharmaceuticals' (NASDAQ:BCRX) Growing Losses Don't Faze Investors as the Stock Spikes 18% This Past Week
There's No Escaping BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Muted Revenues
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11